Lysine specific demethylase 1 (LSD1/KDM1A), a histone modifying enzyme, is upregulated in many cancers, especially in neuro blastoma, breast cancer and hepatoma. We have established a simple method to measure LSD1 activity using a synthetic N terminal 21 mer peptide of histone H3, which is dimethylated at Lys 4 (H3K4me2). After the enzyme reaction, a substrate of H3K4me2 and two demethylated products, H3K4me1 and H3K4me0, were quantitatively determined by flow injection time of flight mass spectrometry (FI TOF/MS). By using recombinant human LSD1, a nonlinear fitting simulation of the data obtained by FI TOF/MS produced typical consecutive reaction kinetics. Apparent K m and k cat values of hLSD1 for the first and second demethylation reactions were found to be in the range of reported values. Tranylcypromine was shown to inhibit LSD1 activity with an IC 50 of 6.9 µM for the first demethylation reaction and 5.8 µM for the second demethylation reaction. The FI TOF/MS assay revealed that the endogenous LSD1 activity was higher in the nuclear extracts of SH SY5Y cells than in HeLa or PC 3 cells, and this is in accordance with the immunoblotting data using an anti LSD1 antibody. A simple, straightforward FI TOF/MS assay is described to efficiently measure LSD1 activity in the nuclear extracts of cultured cells.
Introduction E pigenetic mechanisms are essential for development and differentiation in mammals and epigenetic alterations are key features of cancer, leading to aberrant gene functions. (1, 2) Epigenetic changes in cancers cause a global hypomethylation of genomic DNA that result in genomic instability and activation of growth-promoting genes. Such changes also lead to site-specific hypermethylation of the promoter region CpG islands, which results in silencing tumor-suppressor genes, and a global loss of acetylated histones caused by histone deacetylases. This global loss triggers nucleosome remodeling.
In addition to histone acetylation, lysine methylation of histones is also heavily involved in nucleosome remodeling and gene expression. The methylation status is reversibly regulated by histone lysine methyltransferases and histone lysine demethylases (KDMs). Although a number of KDMs have been identified, lysine-specific demethylase 1 (LSD1, also known as KDM1A, BHC110 or AOF2) has recently received noticeable attention following its identification in 2004. (3) LSD1 is capable of removing dimethyl and monomethyl groups on lysine-4 of histone H3, as well as methyl groups of non-histone proteins such as the tumor suppressor p53 and DNA-methyltransferase 1.
(4) LSD1 is a member of the flavin-dependent amine oxidase (AOF) superfamily, and is similar in 3D structure to monoamine oxidases A and B, and polyamine oxidase. (4, 5) Therefore, tranylcypromine or trans-2-phenylcyclopropylamine (2-PCPA), a pan inhibitor against amine oxidases, is also able to act as a suicide substrate of LSD1 by covalently linking to FAD on the enzyme. (5, 6) LSD2, also known as KDM1B or AOF1, is the only other paralogue of the LSD1 in AOF family and shows the same substrate specificity. (7) LSD2 is rich in oocytes and is thought to participate in genomic imprinting. (8) Overexpression of LSD1 is frequently observed in prostate, breast and bladder cancers, and especially neuroblastoma, where overexpression correlates directly with adverse outcomes and inversely with differentiation in neuroblastic tumors. (9) Thus, LSD inhibitors are potential anticancer agents that may be suitable for application in other human diseases that exhibit mis-regulation of gene expression. For example, 2-PCPA has been shown to induce differentiation of acute myelocytic leukemia with combinatorial use of all-trans retinoic acid (10) and single-handedly suppressed growth of several neuroblastoma cell lines in vitro, as well as neuroblastoma xenograft growth in vivo.
(7) LSD1 currently represents an emerging epigenetic target class for the discovery of novel anti-tumor therapies. (2) By scrutinizing a putative pivotal role of LSD1 in epigenetic regulation of carcinogenesis, it is fundamentally important to assess not only the amount of the protein, but also the enzyme activity in samples. The established assays for LSD1 activity (3, 11) include peroxidase-based measurement of H 2 O 2 production, (12) antibody-based estimation of demethylation products at lysine-4 of histone H3 (13) and mass-spectrometry-based determination of substrate and/or products. (14, 15) Most of these assays use recombinant LSD1 as the enzyme source and several synthetic peptides as the substrate. Several N-terminal truncated enzymes are used and are commercially available, because the N-terminal 184 residue region does not fold into an ordered well defined conformation (11) and the catalytic properties of the Δ184 truncated enzyme are indistinguishable from the activities of longer variants. (16) Forneris et al. (11) revealed that substrate recognition by LSD1 is not confined to the residues neighboring Lys-4 of histone H3, but the enzyme requires a sufficiently long peptide segment containing the N-terminal 20 amino acids of histone H3. Therefore, most of the assays published have used 21-or 25-mer Nterminal peptides that are dimethylated at Lys-4. Numerous assay E kits for screening of LSD1 inhibitors are now commercially available by using these substrates and the recombinant enzyme; however, no assay has revealed endogenous LSD1 enzyme activity in cellular extracts.
The present study describes an assay for measuring LSD1 activity with N-terminal 21-mer peptides of histone H3 using flow injection (FI) based time-of-flight mass spectrometry (TOF/MS). The reaction kinetics of LSD1 from this assay demonstrated typical consecutive kinetics of the demethylation reactions from the dimethylated substrate to the unmethylated product through a monomethylated intermediate in a single reaction tube without any pre-or post-treatment. The FI-TOF/MS assay for LSD1 activity is a novel, label-free approach and the detection of endogenous LSD1 enzyme activity in the nuclear extracts of cultured cells is straightforward.
Materials and Methods
Enzymes and substrates. Highly active recombinant human LSD1 (BML-SE544; hLSD1, aa151-852, 78 kDa, >20 U/μg protein, One U = 1 pmol demethylated/min at 30°C) was purchased from Enzo Life Sciences (Farmingdale, NY). The histone H3 amino-terminal 1-21 peptide with unmethylated Lys-4 or H3K4me0 (#61701), the histone H3 amino-terminal 1-21 peptide with monomethylated Lys-4 or H3K4me1 (#64459) and the histone H3 amino-terminal 1-21 peptide with dimethylated Lys-4 or H3K4me2 (#63677) were purchased from AnaSpec (Fremont, CA). These peptides were dissolved in deionized water and kept frozen at −20°C until use. Recombinant human monoamine oxidase-B (MAOB) (M7441, 15 U/mg protein, One U = 1 nmol deaminated/min at pH 7.4 and 37°C) and trans-2-phenylcyclopropylamine hydrochloride (2-PCPA) were purchased from SigmaAldrich (St. Louis, MO).
Enzyme reaction. A basic reaction mixture consisted of hLSD1 (250 ng = 3.2 pmol) and H3K4me2 (1 nmol) in 50 μl of assay buffer (50 mM Tris-HCl, pH 8.5, 5% glycerol) containing 0.1% bovine serum albumin. After gentle mixing of the reaction mixture on ice, the reactions were initiated by warming in a microtube at 30°C and incubation for 30 min or a designated period. The enzyme reactions were terminated by the addition of acetone at a final concentration of 80% (v/v). To perform precipitation of the peptides efficiently, the resultant acetone mixtures were incubated at room temperature for at least 1 h. The pellets obtained by centrifugation at 20,600 × g for 20 min were washed once with 15 mM ammonium hydroxide, and dissolved in water containing 0.05% trifluoroacetic acid (TFA) with sonication. After brief centrifugation, the resultant extracts were then filtered through a Millex-LG 0.2 μm (Merck Millipore, Darmstadt, Germany) for mass analysis.
Flow injection for time of flight mass spectrometry (FI TOF/MS). We quantitatively measured the LSD1 substrate, H3K4me2, as well as two products of the enzyme reaction, H3K4me1 and H3K4me0 by FI-TOF/MS. The flow rate of the mobile phase (acetonitrile/50 mM formic acid in water = 60/40) was 50 μl/min and was infused with a Waters Acquity UPLC system (Nihon Waters, Tokyo, Japan). Automated FI was performed in duplicate at an injection volume of 2 μl. The histone peptides were ionized by electrospray ionization (ESI) and were detected in a positive ion mode of the TOF/MS system (Waters
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TM QTof MS, Nihon Waters), which was calibrated with sodium formate and lock-sprayed with Leu encephalin (Nihon Waters) each time. The optimal instrument parameters were as follows: a capillary voltage of 3.0 kV, a cone voltage of 30 V, a source temperature of 120°C, and a desolvation temperature of 350°C.
Kinetic analyses. Initial velocities (v 0 ) of hLSD1 were measured at 5 min and then plotted as a function of substrate concentration. The Michaelis-Menten equation (Eq. (1)) was fit to the data using the Prism 6 software (GraphPad Software, San Diego, CA) to calculate the k cat and K m values: LSD1 is a catalyst for consecutive demethylation reactions from H3K4me2 to H3K4me1 and from H3K4me1 to H3K4me0. The first order reaction consists of two consecutive, irreversible elementary steps: (2) where k 1 and k 2 are rate constants for each step. When the reaction starts with an initial concentration of [H3K4me2] 0 , the concentrations of both H3K4me1 and H3K4me0 are zero. The expected concentrations of the three histone-H3 peptides are expressed as a function of time as follows:
The time-course experimental data were applied with nonlinear regression to fit a consecutive reaction model with equations (3), (4) and (5) using the Prism 6 software to calculate the k 1 and k 2 values.
Preparation of nuclear extracts. The human neuroblastomaderived SH-SY5Y cell line was obtained from ATCC (Manassas, VA), and human adenocarcinoma HeLa and human prostate tumor PC-3 cell lines were provided by the RIKEN BRC (Tsukuba, Japan). SH-SY5Y and HeLa cells were cultured in D-MEM (4,500 mg/L glucose, Wako Pure Chem. Ind., Ltd., Osaka, Japan) and PC-3 cells were cultured in RPMI-1640 (Wako Pure Chem.) supplemented with 10% heat-inactivated fetal bovine serum (Thermo Scientific Hyclone, Yokohama, Japan). At 80% confluence, cells were detached by a cell lifter and suspended in ice-cold phosphate buffered saline containing 1 mM phenylmethanesulfonyl fluoride (PMSF, Sigma Aldrich). Nuclear extracts were then prepared by the following procedures. The detached cells were collected by centrifuge at 300 × g for 5 min, and cells were washed with a resuspension buffer (10 mM TrisHCl, pH 8.0, 10 mM KCl, 3 mM MgCl 2 , protease inhibitor cocktail [cOmplete Mini, Roche Diagnostics K.K., Tokyo, Japan], 1 mM PMSF and 0.5 mM dithiothreitol [DTT] ). The cells were resuspended in the resuspension buffer containing 0.1% NP-40. After incubation on ice for 10-20 min, the nuclei were visually confirmed under the microscope. After centrifugation at 550 × g for 5 min, the nuclei were washed with the resuspension buffer. The nuclear pellets were resuspended with the assay buffer containing cOmplete Mini, 1 mM PMSF and 0.5 mM DTT, and homogenized by sonication (10 s × 6, interval = 30 s, amplitude = 20%) with a Sonifier 250 (Branson Ultrasonics Corporation, Danbury, CT). After centrifugation (20,600 × g, 20 min), the supernatant was kept as nuclear extracts. The protein concentrations were measured with the DC Protein Assay kit (Bio-Rad Laboratories, Hercules, CA). The nuclear extracts were used as an enzyme source in place of the recombinant hLSD1 for the FI-TOF/ MS LSD1 assay described above.
Immunoblotting. The nuclear extracts (4 μg protein equiv.) were denatured in 6× sample buffer (0.4 M Tris-HCl, pH 6.8, 12% SDS, 45% glycerol, 0.024% bromophenol blue and 10% 2-mercaptoethanol) by boiling at 95°C for 5 min, resolved by SDS-PAGE and transferred to a PVDF membrane. The membrane was incubated with a polyclonal anti-LSD1 antibody (1:1000, #2139, Cell Signaling Technology, Danvers, MA). Luminescence was produced by incubation with the SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Scientific, Rockford, IL) and detected by using a LAS-1000 imaging system (GE Healthcare Japan, Tokyo, Japan). Collected images were analyzed by the ImageJ software (U.S. National Institutes of Health, Bethesda, MD).
Results and Discussion
FI TOF/MS assay development. Initially, the identification of positive ions from the substrate H3K4me2 by FI-TOF/MS was performed. The accurate monoisotopic mass of H3K4me2 is calculated to be 2281.346 from its molecular formula ( (
The above-mentioned four major ion species found in the present study formed as an isotopic envelope as shown in the lower half of panel A of Fig. 1 . In other words, the putative
n+ (n = 3-6) ions were surrounded with several equally spaced ions at a given "n" on each mass spectrum, so that a trivalent ion cluster gave a 0.33 m/z interval, the tetravalent ion gave an m/z interval of 0.25, the pentavalent ion gave an m/z interval of 0.20 and the hexavalent ion gave a m/z interval of 0.17. These numbers all sum to 1.0 if each interval is multiplied by their respective valency, suggesting that these clusters consist of isotopic equivalent ions containing additional neutrons to varying degrees. Therefore, we tentatively assigned [ (Fig. 1B and C) .
Although
4+ , in combination with the isotopic envelope gave a straight line (y = 74.39x, R 2 = 0.9835, Fig. 2A ). Similar results on the linearity of standard curves were obtained with the pentavalent ion envelope, but the trivalent and hexavalent ion envelopes gave shallower slopes ( Fig. 2A) . The same observations were true with both H3K4me1 and H3K4me0, but the ionization efficiency was clearly dependent on the methylation status; the unmethylated peptide was less efficiently ionized than both methylated peptides (Fig. 2B and C) .
Monitoring hLSD1 reactions by FI TOF/MS. We then analyzed the positive mass ions in the reaction mixture containing the hLSD1 substrate and its products after acetone precipitation followed by solubilization in water containing 0.05% TFA (Fig. 3) . Fig. 3A clearly shows that prior to the hLSD1 reaction only the substrate ions from the H3K4me2 peptide were detected as a characteristic isotopic envelope of the tetravalent ions in the range of 560 to 575 m/z(+). The total MS signals of the tetravalent ions detected were ~60% of the MS signals from an equi-amount of the pure substrate precipitated by acetone and then dissolved in water containing 0.05% TFA, indicating that some ion suppression caused by matrix effects of the enzyme solution did occur. , respectively (Fig. 3B) . Indeed, the differences in m/z between these three isotopic envelopes in panel B were 3.504, which is the number that exactly corresponds to the monoisotopic mass number of 12 4+ had also decreased in amount (Fig. 3C) . Among the multivalent ions from H3K4me2, H3K4me1 and H3K4me0, we decided to monitor the tetravalent ions from the histone peptides to trace the LSD1 reactions, because the tetravalent ions of the three molecular species were more efficiently detected than the tri-, penta-and hexavalent ions (Fig. 1A and 2 ).
Simulation analysis of the consecutive reactions. Fig. 3D clearly shows an hLSD1 reaction time course of a typical Fig. 3 . Detection of monomethyl(K4) and unmethyl(K4) histone H3 (1-21) peptides after the LSD1 reaction. (A) Positive ion mass spectrum of the acetone treated extract (2 μl injected) from a reaction mixture (50 μl) of H3K4me2 (1 nmol) with hLSD1 (3.2 pmol), which was recorded prior to incubation at 30°C. The tetravalent H3K4me2 isotopic envelope was detected at m/z of 571-573. (B) Positive ion mass spectrum of the acetone treated extract (2 μl injected) from a reaction mixture (50 μl) of H3K4me2 (1 nmol) with hLSD1 (3.2 pmol), which was recorded 20 min after the reaction had started. The tetravalent H3K4me1 ion cluster was smaller than H3K4me2 by 3.50 m/z, which corresponds to an m/z of (CH 2 )/4. The [H3K4me0]
4+ ion cluster was smaller by a further 3.50 m/z. (C) The positive ion mass spectrum of the acetone treated extract (2 μl injected) from a reaction mixture (50 μl) of H3K4me2 (1 nmol) with hLSD1 (3.2 pmol), which was recorded at 120 min after the reaction started. (D) Typical consecutive reaction kinetics from H3K4me2 to H3K4me0 through H3K4me1 catalyzed by hLSD1 revealed by FI TOF/MS. H3K4me2 (1 nmol) was incubated with hLSD1 (3.2 pmol) at 30°C. At the indicated time points, the reaction was terminated by adding 4 vol. of acetone and the resultant precipitates were extracted in a 0.05% TFA solution. After filtration through Millex LG 0.2 μm, FI TOF/MS was conducted to measure the amounts of H3K4me2 (•), H3K4me1 (■) and H3K4me0 (▲) by integration of each of the major tetravalent ions (four of them). The peak areas (AUC) of each MS signal on the mass chromatogram were plotted against the reaction time. Data are expressed as mean ± SD (n = 3). (E) Typical consecutive reaction kinetics from H3K4me2 to H3K4me0 through H3K4me1 catalyzed by hLSD1 revealed by FI TOF/MS. By using the data shown in panel E, a simulation of first order consecutive reaction kinetics was performed by GraphPad Prism 6, which was installed with Equations "(3); k 1 ) )", indicating exponential decay, transient peak and sigmoidal accumulation curves in each molecular species such as H3K4me2 ( •), H3K4me1 (■) and H3K4me0 (▲). The amounts (pmol/reaction) of each species were plotted against the reaction time. Data are expressed as mean ± SD (n = 3).
was observed to decay exponentially and the intermediate product H3K4me1 transiently increased exponentially to a maximum after 20 min reaction time and then gradually decreased, whereas the final product H3K4me0 gradually accumulated in a sigmoidal fashion.
We then performed a nonlinear global simulation of these reaction time-course data using Equations (3), (4) and (5) with the GraphPad Prism 6 software to calculate k 1 and k 2 . As a result, k 1 (8.08 × 10 −2 ± 4.52 × 10 −3 pmol/min) was slightly larger than k 2 (6.02 × 10 −2 ± 3.82 × 10 −3 pmol/min) with a high goodness (R 2 = 0.9404) of fit to a first-order consecutive reactions model (nonlinear fitting by GraphPad Prism 6, Fig. 3E) .
Plant et al. (14) also demonstrated a time course of the recombinant LSD1 reaction by monitoring three histone H3 peptides with a label-free MS/MS assay; however, they showed a linear rather than an exponential decay of H3K4me2 (1-25) until 120 min. Their results were quite different from the results presented herein, despite both groups using similar enzymes of N-truncated recombinant human LSD1 (171-852 or 151-852 hLSD1) and similar synthetic N-terminal H3K4me2 peptide substrates (1-25 or 1-21 histone H3). Major differences in the conditions between the assays are the concentrations of hLSD1 (2.5 nM vs 64 nM) and H3K4me2 (0.27 μM vs 20 μM), and the resultant ratios of the substrate to the enzyme (108 vs 312.5), which may explain the different kinetics between the previous report and the results herein. (Fig. 4A) . A typical Michaelis-Menten-type saturation curve was obtained, and the parameters of k cat and K m were found to be 15.8 min −1 and 3.08 μM, respectively, and the value of k cat / K m was calculated to be 5.12 min −1 ·μM −1 . These values for the H3K4me2 N-terminal 1-21 peptide are in reasonable agreement with the values reported previously by Forneris et al. (16) The same kinetics analysis describing the formation of H3K4me0 from H3K4me1 was performed with hLSD1 (Fig. 4B) . As a result, a Prism 6 simulation revealed that k cat was 7.68 min 
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constants of the hLSD1 reaction. The initial velocity (v 0 ) of formation of H3K4me1 + H3K4me0 from H3K4me2 was plotted against the concentrations of H3K4me2 added
·µM
−1 for the demethylation reaction of H3K4me1. Although k cat and the catalytic efficiency (k cat /K m ) of the second reaction were in the same range as those of the first reaction, we have not resolved how efficiently LSD1 catalyze a sequential demethylation of H3K4me1 produced from H3K4me2 on the catalytic site of the enzyme. The enzymeproduced H3K4me1 may not be extensively distributed in the reaction mixture, which may cause a higher catalytic efficiency than the measured catalytic efficiency for the second reaction.
Inhibitory effects of 2 PCPA on hLSD1 activity. To validate the presented FI-TOF/MS assay for measuring hLSD1 activity, we used 2-PCPA, a benchmark inhibitor over a concentration range of 0-100 μM in a reaction mixture (50 μl) containing H3K4me2 (1 nmol) and hLSD1 (3.2 pmol). As shown in Fig. 5A , 2-PCPA inhibited hLSD1-catalyzed production of H3K4me1 and H3K4me0 in a dose-dependent manner with an IC 50 (half maximal inhibitory concentration) of 6.90 μM. In the literature, the reported IC 50 of 2-PCPA for LSD1 is in the range from <2 to 34 μM with the substrate concentrations from 0.27 to 67 μM. (14, 19, 20) When we drew focus to the production of H3K4me0 from H3K4me1, the IC 50 of 2-PCPA was found to be 5.80 µM (Fig. 5B) . Although the second demethylation reaction appears to be more sensitive to 2-PCPA, we cannot directly compare the IC 50 value for the second reaction with that of the first reaction. Inasmuch as 2-PCPA, a well-established suicide substrate for LSD1, covalently binds to FAD of LSD1, the two consecutive reactions should be both affected by 2-PCPA.
Measurement of the endogenous LSD1 activity in the nuclear extracts of cultured cells. To apply the presented FI-TOF/MS assay for measuring endogenous LSD1 activity in cells, we prepared nuclear extracts from three different human cell lines, Fig. 6 . Detection of LSD1 activity in the nuclear extracts of cultured cells. (A) Each nuclear extract (4 μg protein each per lane) was applied onto the SDS PAGE and LSD1 proteins were detected with an anti LSD1 antibody. (B) Total protein staining of the SDS PAGE gel for the nuclear extracts of cultured cells. Nuclear extracts of SH SY5Y, HeLa and PC 3 cells (4 μg protein equiv. per each lane) were separated by SDS PAGE, and total proteins in a gel were stained with Coomassie brilliant blue dye. (C) The density of the LSD1 bands was quantified by ImageJ. The measured LSD1 levels were expressed relative to the density of total protein per each lane in the same gel stained with Coomassie brilliant blue (CBB) dye. Data represent means ± SD (n = 6 for SH SY5Y, n = 4 for HeLa and PC 3). (D) H3K4me2 (1 nmol) was incubated with nuclei extracts (each 10 μg protein) at 30°C for 1 h. LSD1 activity expressed by the amount of H3K4me1 + H3K4me0 produced by the nuclear enzyme. Data were expressed as mean ± SD (n = 4 for SH SY5Y, n = 3 for HeLa and PC 3). *p<0.05, **p<0.01. (E) The nuclear extracts of SH SY5Y cells (10 μg protein) were preincubated on ice with 2 PCPA for 1 h, and then, the enzyme reaction started by adding H3K4me2 (1 nmol) and warming at 30°C. The initial velocity of the enzyme reaction was measured at 1 h and expressed as the produced amount of H3K4me1 + H3K4me0. Data were expressed as mean ± SD (n = 3). (F) Inability of hMAOB to catalyze the demetylation of dimethyl(K4) histone H3 (1 21) peptide. H3K4me2 (1 nmol) was incubated with the increasing amounts (0-20 U) of hLSD1 (•) or hMAOB (■) at 30°C for 1 h. FI TOF/MS was conducted to measure the product amounts of H3K4me1 + H3K4me0.
because LSD1 is recognized as a nuclear marker protein.
(3) A major 110-kDa band was detected in the nuclear extracts derived from the three cell lines tested (Fig. 6A) . The cellular amount of LSD1 protein relative to Coomassie blue-stained proteins (Fig. 6B) was the highest in SH-SY5Y cells and the lowest in HeLa cells (Fig. 6C ). In accordance with these immunoblotting data, the FI-TOF/MS assay revealed that the endogenous LSD1 activity was higher in the nuclear extracts of SH-SY5Y cells than those of HeLa or PC-3 cells (Fig. 6D) . As shown in Fig. 6E , the endogenous LSD1 activity was inhibited dose-dependently with 2-PCPA, which is also able to inhibit MAOB, a mitochondrial flavoenzyme. However, we confirmed that recombinant hMAOB was unable to catalyze the demethylation reaction of H3K4me2 (Fig. 6F) , suggesting that 2-PCPA inhibition in the nuclear extracts of SH-SY5Y cells is a manifestation of the nuclearlocalized active LSD1 enzyme. However, we cannot exclude the possibility that some other endogenous enzymes may be involved in demethylation reactions in our assay. The only one paralogue of LSD1 so far reported is LSD2/KDM1B, which is able to demethylate a substrate of H3K4me2 (1-21) peptide, but not H3R2me1K4me1 peptide that is a substrate for LSD1. But, the remaining 20% activity at 50 μM 2-PCPA (Fig. 6E) could not be provided by a putative LSD2 in SH-SY5Y cells, because LSD2 is also sensitive to 2-PCPA treatment.
(7) The expression profiles of LSD2 have now been scarcely available in the literatures so that we have no information about endogenous LSD2 activity in SH-SY5Y cells. In the immediate future, H3R2me1K4me1 will be commercially available and can be utilized for more specific assay of LSD1 activity.
Finally, it is worthwhile to mention that the LSD1 enzyme activity could be modulated by the protein-protein interaction with other nuclear proteins such as CoREST, NuRD, (21) nuclear transcription factors (estrogen receptor and androgen receptor) (22) and HDAC. (23) Furthermore, some small-molecular agents such as resveratrol and curcumin were reported to inhibit LSD1 activity. (24) We recently also found that several acyclic diterpenoids directly inhibit recombinant human LSD1 activity at their micromolar concentrations.
(25) Therefore, we must be careful to assess the epigenetic role of LSD1, the enzyme activity of which may not correlate its protein levels evaluated by western blotting.
In conclusion, the present study describes a novel assay for LSD1 activity using FI-TOF/MS, and an N-terminal 21-mer peptide of histone H3 with methylated Lys-4. The assay revealed typical first-order consecutive kinetics of the demethylation reactions, in which the dimethylated substrate is converted to the unmethylated product through a monomethylated intermediate in a single reaction tube without any pre-or post-treatment requirements. Furthermore, the FI-TOF/MS assay for LSD1 unequivocally detected the enzyme activity in the nuclear extracts of three human cell lines.
